ID 19 Flashcards
griseofulvin uses
1) oral treatment of superficial infections
2) inhibits growth of dermatophytes (tinea, ringworm)
other griseofulvin AE
metabolizes Warfarin
permethrin MOA
blocks sodium channels (*thus neurotoxic)
malathion mechanism
acetylcholisterase inhibitor
lindane mechanism
blocks GABA channels (*thus neurotoxic)
chloroquine MOA
blocks detoxification of heme into hemozoin –> heme accumulates and is toxic to plasmodia
resistance to chloroquine?
membrane pump that decreases intracellular concentration of drug.
only drug you can’t use chloroquine for?
p falciparum
p falciparum treatment options
1) artemether/lumefantrine
2) atovaquone/proguanil
life-threatening malaria treatment
artesunate
*quinidine in US (quinine elsewhere)
chloroquine AE’s
retinopathy
pruritus (especially in dark-skinned individuals)
drug like oseltamivir…
zanamivir
oseltamivir/zanamivir uses
treatment and prevention of both influenza A and B
Why do acyclovir/valacyclovir have few adverse effects in uninfected cells?
not phosphorylated
acyclovir/valacyclovir usage caveat
no effect on latent forms of HSV and VZV
difference between valacyclovir and acyclovir?
valacyclovir is a prodrug of acyclovir that has better oral bioavailability
acyclovir/valacyclovir MOA of resistance
mutated viral thymidine kinase
acyclovir/valacyclovir AE’s
1) Obstructive crystalline nephropathy
2) ARF
Ganciclovir MOA
5-monophosphate formed by a CMV viral kinase. Guanosine analog. Triphosphate formed by cellular kinase. Preferentially inhibits viral DNA polymerase.
ganciclovir prodrug
valganciclovir, better oral bioavailability.
ganciclovir MOA of resistance
mutated viral kinase
Foscarnet MOA
Viral DNA/RNA polymerase inhibitor and HIV reverse transcriptase inhibitor.
*binds to pyrophosphate-binding site of enzyme (pyrophosphate analog)
foscarnet vs. ganciclovir/acyclovir
foscarnet doesn’t require kinase activation.
foscarnet uses
1) CMV retinitis in immunocompromised patients when ganciclovir fails
2) acyclovir-resistant HSV
foscarnet AE’s
1) nephrotoxicity
2) electrolyte abnormalities (hypo or hypercalcemia, hypo or hyperphosphatemia, hypokalemia, hypomagnesemia)
3) seizures
MOA of resistance with foscarnet
mutated DNA polymerase
Cidofovir and phosphorylation?
doesn’t require phosphorylatoin
cidofovir MOA
inhibits viral DNA polymerase
cidofovir pharmacokinetics
long half-life
cidofovir uses
1) CMV retinitis in immunocompromised patients
2) acyclovir-resistant HSV
cidofovir AE’s
nephrotoxic
how to reduce cidofovir toxicity?
coadminster with probenecid and IV saline
HAART composition
2 NRTIs + integrase inhibitor
NRTIs
Abacavir (ABC) Didanosine (ddl) Emtricitabine (FTC) Lamivudine (3TC) Stavudine Tenofovir (TDF) Zidovudine (ZDV, formerly AZT)
NRTI MOA
competitively inhibit nucleotide binding to reverse transcriptase and terminate DNA chain (lack a 3’ OH group)
What is unique about Tenofovir?
nucleo”T”ide, unlike nucleoside, and needs to be phosphorylated.
NRTI AE’s
1) bone marrow suppression (reverse with G-CSF and ego)
2) peripheral neuropathy
3) lactic acidosis (nucleosides)
4) anemia (ZDV)
5) pancreatitis (didanosine)
thing to remember about abacavir
contraindicated if patient has a HLA-B5701 mutation
NNRTIs
Delaviridine
Efavirenz
Nevirapine
NNRTI mechanism
bind reverse transcriptase at site different from NRTIs.
*no phosphorylation required.
NNRTI AE’s
1) rash
2) hepatotoxic
3) efavirenz – vivid dreams + CNS symptoms
4) delavirdine and efavirenz contraindicated in pregnancy
protease inhibitors
all the -navirs
protease inhibitor that’s a CYP-45O inhibitor…
ritonavir
protease inhibitor AE’s
Hyperglycemia
GI intolerance (nausea, diarrhea)
lipodystrophy (Cushing-like syndrome
Nephropathy, hematuria (indinavir)
protease inhibitor contraindicaion
rifampin (potent CYP/UGT inducer) that can decrease concentration.
integrase inhibitors
raltegravir
elvitegravir
dolutegravir
integrase inhibitor AE
increase creatine kinase
enfuvurtide AE
skin reaction at injection sites
enfuvirtide MOA
Binds gp41, inhibiting viral entry
maraviroc MOA
binds CCR-5 on surface of T cells/monocytes inhibiting interaction with gp120